| Withdrawn | CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosu NCT06752876 | Caribou Biosciences, Inc. | Phase 1 |
| Not Yet Recruiting | Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress NCT06999109 | Duke University | N/A |
| Not Yet Recruiting | Cardiac Imaging in Systemic Disorders: the ORACLES Registry NCT07134166 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Safety and Efficacy of ONT01 in Lupus NCT07107659 | Hospital for Special Surgery, New York | EARLY_Phase 1 |
| Recruiting | Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease an NCT07262983 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Not Yet Recruiting | Complete Cognitive Intervention for cSLE NCT07302113 | Andrea Knight | N/A |
| Recruiting | Helping Lupus Patients Manage Fibromyalgia Symptoms Through Emotional Awareness and Expression Therapy (EAET) NCT07282392 | University of Utah | N/A |
| Recruiting | Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Lupu NCT05018858 | The Foundation for Orthopaedics and Regenerative Medicine | Phase 1 |
| Completed | The Burden of Lupus in Canada From a Patient Perspective: A Canadian Real-World PROxy Study NCT07267091 | PeriPharm | — |
| Not Yet Recruiting | Direct to Patient Minimal Risk Biospecimen and Data Collection Research NCT07128966 | Joined Bio | — |
| Recruiting | CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus NCT06839976 | Children's Hospital of Philadelphia | Phase 1 / Phase 2 |
| Recruiting | UC-MSC Cell Therapy Study for Systemic Lupus Erythematosus (SLE) Patients NCT06737380 | LiveKidney.Bio | Phase 1 |
| Not Yet Recruiting | Ultrasonic COmparison of Salivary Glands in Autoimmune Diseases (COUGAR) NCT06680310 | University Hospital, Brest | — |
| Completed | S100A8 in Serum and Urine as a New Biomarker in Lupus Nephritis NCT06872138 | Theodor Bilharz Research Institute | — |
| Recruiting | Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Aut NCT06434363 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Clarifying Misbeliefs About Hydroxychloroquine: Developing a Decision Aid for Patients With Lupus NCT05922722 | University of Wisconsin, Madison | — |
| Recruiting | A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participa NCT06013995 | Bristol-Myers Squibb | Phase 1 |
| Recruiting | Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research NCT04806620 | Brain Inflammation Collaborative | — |
| Active Not Recruiting | Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity NCT05715463 | Brigham and Women's Hospital | N/A |
| Recruiting | Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRE NCT05612750 | Stanford University | N/A |
| Unknown | Aerobic Exercise Versus Whole-Body Vibration on Fatigue, Functional Capacity, Quality of Life in Systemic Lupu NCT05321108 | Cairo University | N/A |
| Recruiting | Deployment o the Multidisciplinary Prospective Cohort Imminent NCT04334031 | University Hospital, Lille | N/A |
| Terminated | Acceptability and Persistence of the Use of a Patient-centred E-health Tool for Lupus Patients Followed in a S NCT03953690 | Centre Hospitalier Universitaire Dijon | — |
| Recruiting | Patient-Centered Assessment of Symptoms and Outcomes NCT03952624 | National Center for Complementary and Integrative Health (NCCIH) | — |
| Completed | A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets NCT04065932 | Bristol-Myers Squibb | Phase 1 |
| Suspended | A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease NCT04031469 | ProgenaBiome | — |
| Completed | Evaluation of MyoStrain™ in Clinical Practice NCT03825224 | University of Kansas Medical Center | — |
| Terminated | Aerobic Exercise in Women With Systemic Lupus Erythematosus NCT03186794 | National Institutes of Health Clinical Center (CC) | N/A |
| Completed | A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients NCT03402087 | Bristol-Myers Squibb | Phase 1 |
| Completed | JBT-101 in Systemic Lupus Erythematosus (SLE) NCT03093402 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Unknown | Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization NCT03142412 | DxTerity Diagnostics | — |
| Completed | Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus NCT02265744 | Bristol-Myers Squibb | Phase 2 |
| Terminated | Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus NCT01389895 | Amgen | Phase 1 |
| Terminated | Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus NCT01164917 | Amgen | Phase 1 |
| Unknown | Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis NCT01172002 | RenJi Hospital | N/A |
| Completed | Transcultural Validation in French of the Systemic Lupus Activity Questionnaire (SLAQ) and the Lupus Quality O NCT02857452 | Centre Hospitalier Universitaire Dijon | — |
| Completed | Vitamin D3 in Systemic Lupus Erythematosus NCT00710021 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus NCT00657189 | MedImmune LLC | Phase 2 |
| Completed | A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Sys NCT00482989 | MedImmune LLC | Phase 1 |
| Completed | Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE) NCT00299819 | MedImmune LLC | Phase 1 |
| Completed | Improving Quality of Life for African American Female Adolescents With Lupus NCT00068874 | Medical University of South Carolina | Phase 2 |
| Completed | Disease Progression and Activity in Patients With Systemic Lupus Erythematosus NCT00339261 | National Institute of Environmental Health Sciences (NIEHS) | — |
| Completed | Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE) NCT00054938 | Brigham and Women's Hospital | Phase 2 |
| Unknown | To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids NCT00053560 | Genelabs Technologies | Phase 3 |
| Completed | Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies NCT00581763 | University of California, San Francisco | — |